Cargando…

Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial

INTRODUCTION: Remifentanil is an opioid with a unique pharmacokinetic profile. Its organ-independent elimination and short context-sensitive half time of 3 to 4 minutes lead to a highly predictable offset of action. We tested the hypothesis that with an analgesia-based sedation regimen with remifent...

Descripción completa

Detalles Bibliográficos
Autores principales: Muellejans, Bernd, Matthey, Thomas, Scholpp, Joachim, Schill, Markus
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550941/
https://www.ncbi.nlm.nih.gov/pubmed/16780597
http://dx.doi.org/10.1186/cc4939
_version_ 1782129309260972032
author Muellejans, Bernd
Matthey, Thomas
Scholpp, Joachim
Schill, Markus
author_facet Muellejans, Bernd
Matthey, Thomas
Scholpp, Joachim
Schill, Markus
author_sort Muellejans, Bernd
collection PubMed
description INTRODUCTION: Remifentanil is an opioid with a unique pharmacokinetic profile. Its organ-independent elimination and short context-sensitive half time of 3 to 4 minutes lead to a highly predictable offset of action. We tested the hypothesis that with an analgesia-based sedation regimen with remifentanil and propofol, patients after cardiac surgery reach predefined criteria for discharge from the intensive care unit (ICU) sooner, resulting in shorter duration of time spent in the ICU, compared to a conventional regimen consisting of midazolam and fentanyl. In addition, the two regimens were compared regarding their costs. METHODS: In this prospective, open-label, randomised, single-centre study, a total of 80 patients (18 to 75 years old), who had undergone cardiac surgery, were postoperatively assigned to one of two treatment regimens for sedation in the ICU for 12 to 72 hours. Patients in the remifentanil/propofol group received remifentanil (6- max. 60 μg kg(-1 )h(-1); dose exceeds recommended labelling). Propofol (0.5 to 4.0 mg kg(-1 )h(-1)) was supplemented only in the case of insufficient sedation at maximal remifentanil dose. Patients in the midazolam/fentanyl group received midazolam (0.02 to 0.2 mg kg(-1 )h(-1)) and fentanyl (1.0 to 7.0 μg kg(-1 )h(-1)). For treatment of pain after extubation, both groups received morphine and/or non-opioid analgesics. RESULTS: The time intervals (mean values ± standard deviation) from arrival at the ICU until extubation (20.7 ± 5.2 hours versus 24.2 h ± 7.0 hours) and from arrival until eligible discharge from the ICU (46.1 ± 22.0 hours versus 62.4 ± 27.2 hours) were significantly (p < 0.05) shorter in the remifentanil/propofol group. Overall costs of the ICU stay per patient were equal (approximately €1,700 on average). CONCLUSION: Compared with midazolam/fentanyl, a remifentanil-based regimen for analgesia and sedation supplemented with propofol significantly reduced the time on mechanical ventilation and allowed earlier discharge from the ICU, at equal overall costs.
format Text
id pubmed-1550941
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15509412006-08-22 Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial Muellejans, Bernd Matthey, Thomas Scholpp, Joachim Schill, Markus Crit Care Research INTRODUCTION: Remifentanil is an opioid with a unique pharmacokinetic profile. Its organ-independent elimination and short context-sensitive half time of 3 to 4 minutes lead to a highly predictable offset of action. We tested the hypothesis that with an analgesia-based sedation regimen with remifentanil and propofol, patients after cardiac surgery reach predefined criteria for discharge from the intensive care unit (ICU) sooner, resulting in shorter duration of time spent in the ICU, compared to a conventional regimen consisting of midazolam and fentanyl. In addition, the two regimens were compared regarding their costs. METHODS: In this prospective, open-label, randomised, single-centre study, a total of 80 patients (18 to 75 years old), who had undergone cardiac surgery, were postoperatively assigned to one of two treatment regimens for sedation in the ICU for 12 to 72 hours. Patients in the remifentanil/propofol group received remifentanil (6- max. 60 μg kg(-1 )h(-1); dose exceeds recommended labelling). Propofol (0.5 to 4.0 mg kg(-1 )h(-1)) was supplemented only in the case of insufficient sedation at maximal remifentanil dose. Patients in the midazolam/fentanyl group received midazolam (0.02 to 0.2 mg kg(-1 )h(-1)) and fentanyl (1.0 to 7.0 μg kg(-1 )h(-1)). For treatment of pain after extubation, both groups received morphine and/or non-opioid analgesics. RESULTS: The time intervals (mean values ± standard deviation) from arrival at the ICU until extubation (20.7 ± 5.2 hours versus 24.2 h ± 7.0 hours) and from arrival until eligible discharge from the ICU (46.1 ± 22.0 hours versus 62.4 ± 27.2 hours) were significantly (p < 0.05) shorter in the remifentanil/propofol group. Overall costs of the ICU stay per patient were equal (approximately €1,700 on average). CONCLUSION: Compared with midazolam/fentanyl, a remifentanil-based regimen for analgesia and sedation supplemented with propofol significantly reduced the time on mechanical ventilation and allowed earlier discharge from the ICU, at equal overall costs. BioMed Central 2006 2006-06-15 /pmc/articles/PMC1550941/ /pubmed/16780597 http://dx.doi.org/10.1186/cc4939 Text en Copyright © 2006 Muellejans et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Muellejans, Bernd
Matthey, Thomas
Scholpp, Joachim
Schill, Markus
Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
title Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
title_full Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
title_fullStr Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
title_full_unstemmed Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
title_short Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
title_sort sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550941/
https://www.ncbi.nlm.nih.gov/pubmed/16780597
http://dx.doi.org/10.1186/cc4939
work_keys_str_mv AT muellejansbernd sedationintheintensivecareunitwithremifentanilpropofolversusmidazolamfentanylarandomisedopenlabelpharmacoeconomictrial
AT mattheythomas sedationintheintensivecareunitwithremifentanilpropofolversusmidazolamfentanylarandomisedopenlabelpharmacoeconomictrial
AT scholppjoachim sedationintheintensivecareunitwithremifentanilpropofolversusmidazolamfentanylarandomisedopenlabelpharmacoeconomictrial
AT schillmarkus sedationintheintensivecareunitwithremifentanilpropofolversusmidazolamfentanylarandomisedopenlabelpharmacoeconomictrial